Breaking News
Investing Pro 0
Final hours: unlock premium data with Claim 60% OFF

Sandoz dials up product launch plans ahead of market debut

Published Sep 15, 2023 02:05AM ET Updated Sep 15, 2023 02:16AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder/File Photo
 
PFE
-0.59%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NOVN
+0.13%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
REGN
+1.61%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BAYRY
-1.39%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ABBV
+1.11%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BIIB
+2.24%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Ludwig Burger and Paul Arnold

FRANKFURT (Reuters) - Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland's Novartis (SIX:NOVN) works to enhance its investor appeal ahead of its market debut next month.

Its launch ambitions come as Novartis shareholders are widely expected to sign off on the Sandoz spin-off at an extraordinary general meeting on Friday.

Sandoz, whose first day of trading is scheduled for Oct. 4, has previously said its development pipeline has 25 future biosimilars, cheaper versions of off-patent biologic drugs made from modified living cells, five of which it aims to bring to market over the next two years.

"When I joined (in 2019), there were less than eight biologics in the pipeline. Today, there's 25. And that journey will continue. I'll be happier when it's over 30," Saynor told Reuters in an interview.

Sandoz is currently the world's second-largest maker of biosimilars behind Pfizer (NYSE:PFE). Saynor said dethroning the U.S. pharma giant, whose focus is on developing new drugs rather than copying others, is "very much" his goal.

Deutsche Bank estimates that Sandoz, which accounted for 11% of Novartis' group operating profit in 2022, is likely to have a market value of $11-$13 billion, with brokerage Berenberg expecting a $17-$26 billion valuation range.

Saynor said new biosimilar product launches in Europe and the United States, as blockbuster drugs lose patent protection, were key to reaching the company's growth and margin targets.

The existing production network and sales force can absorb foreseeable launches, resulting in sales growing much faster than costs, he added.

"Whatever we launch, it's accretive to our business," he said, adding that major takeover deals were not on his agenda.

Sandoz, which generated more than $9 billion in revenue last year, needs biosimilars to boost profitability, which has been weighed down by higher marketing expenses and cost inflation.

The more profitable biosimilars currently account for only about a fifth of sales. The rest of the business is dominated by conventional chemical drugs, which are under price pressure.

The Swiss company has said that adjusted core profit margins would likely be 18-19% this year, down from 21.3% in 2022, but it aims for margins to rebound to between 24% to 26% by 2028.

Sales should grow by a "mid-single digit" percentage over the period, it has said.

Among the biotech mega-sellers that Sandoz is seeking to copy are Biogen (NASDAQ:BIIB)'s multiple sclerosis drug Tysabri, AbbVie (NYSE:ABBV)'s rheumatoid arthritis drug Humira, Amgen (NASDAQ:AMGN)'s bone cancer drug Prolia, also known as Xgeva, and Bayer (OTC:BAYRY) and Regeneron (NASDAQ:REGN)'s eye drug Eylea with more than $40 billion in annual sales between them.

But companies such as Amgen, Fresenius, Organon, Teva and unlisted Boehringer Ingelheim are also competing in the biosimilars market.

Sandoz, which will be included in Switzerland's mid-cap SMIM index, said this week it plans to launch a generic version of Johnson & Johnson (NYSE:JNJ)'s anti-inflammatory drug Stelara.

Sandoz dials up product launch plans ahead of market debut
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email